Professional Documents
Culture Documents
Generic Name/ Trade Name/ Form of Medication
Generic Name/ Trade Name/ Form of Medication
Generic Name/ Trade Name/ Form of Medication
Epoetin Haematop 500 units Mimics effect of Treatment of -Poorly CNS: -Before starting
Beta oietic subcutane erythropoietin. anemia controlled Headache, therapy,
evaluate
(Recormon) drugs ous twice Functions as associated with HTN seizures,
patient’s iron
a week growth factor, chronic renal -Not to be paresthesia, status. Patient
Peak: 5-24 enhancing RBC failure on or not used if the fatigue, should receive
hrs. production on dialysis and indication is dizziness, adequate iron
malignancy on for increasing asthenia supplementation
or not on the yield of CV: beginning no
later than when
chemotherapy autologous hypertension, epoetin
blood if mth edema, treatment starts
preceding increased and continuing
treatment of clotting of throughout
patient arteriovenous therapy. Patient
also may need
suffered MI, grafts
vitamin B12 and
stroke, EENT: folic acid
unstable Pharyngitis -Monitor BP
angina G.I: before therapy.
pectoris, or at Nausea, Most patients
risk of vomiting, with chronic
renal
DVT,history abdominal pain failure have
of Metabolic: hypertension. BP
thromboembo Hyperuricemia, may
lic disease. hyperkalimia, Increase,
hyperphosphate especially when
hematocrit
mia
Respiratory: increases in the
Cough, early part of
therapy
shortness of -institute diet
breath restrictions or
Skin : drug therapy to
Rash, infection control BP
site reactions, -monitor
hemoglobin level
urticaria
twice weekly
Other: pyrexia until it stabilizes
in the target
range (10 to 12
g/dl for most
patients) and
maintenance
dose is
established, then
continue to
monitor at
regular intervals.
Resume twice
weekly testing
following any
dosage
adjustments
-reduce dosage
in patients who
have an increase
in hemoglobin
level of more
than 1 g/dl in any
2 week period
-monitor blood
counts; elevated
hematocrit may
cause excessive
clotting
-patient may
need additional
heparin to
prevent clotting
treatments
-evaluate patient
who experiences
a lack or loss of
effect for pure
red cell aplasia
Patient teaching
-inform patient
that pain or
discomfort in
limbs (long
bones) and
pelvis, and
coldness and
sweating may
occur after
injection (usually
within 2 hours)
symptoms may
last for 12 hours
and then
disappear
-advise patient to
avoid driving or
operating heavy
machinery at
start of therapy.
There may be a
relationship
between too
rapid increase
hematocrit and
seizures
-Tell patient to
monitor BP at
home and
adhere
dietary
restrictions
Collaborative:
Administer medication Infused on
as indicated, e.g: arterial side
Heparin (low dose) of filter to
prevent
clotting in
the filter
without
systemic
side effects